M. Kato

发表

Hepatic Toll‐like receptor 3 expression in chronic hepatitis C genotype 1 correlates with treatment response to peginterferon plus ribavirin

S. Matsumoto, T. Yamaguchi, N. Yuki, 2010, Journal of viral hepatitis.

GBV‐C/HGV infection in chronic hepatitis C patients: Its effect on clinical features and interferon therapy

N. Hayashi, A. Kasahara, N. Hiramatsu, 1998, Journal of medical virology.

Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.

A. Kasahara, H. Fusamoto, A. Inoue, 1997, Journal of hepatology.

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha‐2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses

Y. Imai, N. Hayashi, A. Kasahara, 2010, Journal of viral hepatitis.

Pegylated interferon alpha‐2b (Peg‐IFN α‐2b) affects early virologic response dose‐dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg‐IFN α‐2b plus ribavirin

Y. Imai, N. Hayashi, A. Kasahara, 2009, Journal of viral hepatitis.

Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: Relationship to the therapeutic response

N. Hayashi, A. Kasahara, N. Hiramatsu, 2001, Journal of gastroenterology and hepatology.

Serial quantitative analysis of serum hepatitis C virus RNA level in patients with acute and chronic hepatitis C.

N. Hayashi, A. Kasahara, H. Fusamoto, 1994, Journal of hepatology.

Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients.

N. Hayashi, H. Fusamoto, K. Ohkawa, 1994, Journal of hepatology.

Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirin

Y. Imai, N. Hayashi, A. Kasahara, 2009, Journal of viral hepatitis.

The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1

Y. Imai, N. Hayashi, A. Kasahara, 2015, Journal of viral hepatitis.

Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients.

M. Komori, A. Kaneko, K. Mochizuki, 2001, Journal of hepatology.

Evaluation of combined therapy with chemoembolization and ethanol injection for advanced hepatocellular carcinoma.

H. Ishida, T. Michida, A. Kaneko, 1997, Seminars in oncology.

Clinical implications of coinfection with a novel DNA virus (TTV) in hepatitis C virus carriers on maintenance hemodialysis

N. Hayashi, Y. Sasaki, M. Hori, 1999, Journal of medical virology.

Treatment with Recombinant Interferon-α2a for Patients with Chronic Hepatitis C: Predictive Factors for Biochemical and Virologic Response

A. Kasahara, H. Fusamoto, T. Kamada, 1996 .

Disease stage of chronic hepatitis C assessed by both peritoneoscopic and histologic findings and its relationship with response to interferon therapy.

N. Hayashi, A. Kasahara, H. Fusamoto, 1997, Gastrointestinal endoscopy.

Reappraisal of biochemical hepatitis C activity in hemodialysis patients.

N. Hayashi, Y. Sasaki, M. Hori, 2000, Journal of clinical gastroenterology.

Clinical applications of ICG Finger Monitor in patients with liver disease.

K. Awazu, M. Kanda, K Awazu, 1993, Journal of hepatology.

Pegylated interferon alpha‐2b (Peg‐IFN α‐2b) affects early virologic response dose‐dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg‐IFN α‐2b plus ribavirin

Y. Imai, A. Kasahara, N. Hiramatsu, 2009, Journal of viral hepatitis.